Recent News

2019 | 2018 | 2017 | 2016 | 2015 | 2014

09-17-19 ImmuCell Enters into Lease Agreement for a Facility to Expand First Defense® Production Capacity

09-11-19 ImmuCell Announces an Agreement Covering the Formulation and Aseptic Filling of Syringes for Re-Tain™

08-29-19 ImmuCell Receives FDA Response To First CMC Submission for Re-Tain™

08-12-19 ImmuCell Announces Unaudited Financial Results for Second Quarter of 2019

08-06-19 ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2019

05-13-19 ImmuCell Announces Unaudited Financial Results for First Quarter of 2019

05-07-19 ImmuCell to Announce Unaudited Financial Results for First Quarter of 2019

03-29-19 ImmuCell Corporation Announces Closing of $9 Million Public Offering of Common Stock

03-27-19 ImmuCell Corporation Announces Pricing of $9.0 Million Public Offering of Common Stock

03-26-19 ImmuCell Corporation Announces Commencement of Public Offering of Common Stock

02-28-19 ImmuCell Announces Submission of Manufacturing Technical Section for its Purified Nisin Product

02-13-19 ImmuCell Announces Preliminary Financial Results for Fourth Quarter and Full Year 2018

02-06-19 ImmuCell to Announce Financial Results for Fourth Quarter and Full Year 2018